|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Baker Bros Advisors LP
✚
|
|
|---|---|
| CRD # | 158149 |
| SEC # | 801-73446 |
| CIK # | 0001263508 |
| AUM | $18.0 B (2025-03-28) |
| Employees | 56 (34% Investors, 0% Brokers) |
| Phone | 212-339-5600 |
| Address | 860 Washington Street, 3rd Floor New York, NY 10014 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| BeiGene Ltd | 2.1 | ||
| Incyte Corp | 2.1 | ||
| Acadia Pharmaceuticals Inc | 0.9 | ||
| Insmed Inc | 0.8 | ||
| Summit Therapeutics PLC | 0.7 | ||
| Synta Pharmaceuticals Corp | 0.6 | ||
| Rhythm Pharmaceuticals Inc | 0.4 | ||
| Revolution Medicines Inc | 0.3 | ||
| Kymera Therapeutics Inc | 0.3 | ||
| Alkermes PLC | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| HF | 14159 LP | 2012-02-13 | 17.0 | |
| HF | 667 LP | 2012-02-13 | 1,493.8 | |
| HF | Baker Biotech Fund II A LP | 2012-02-13 | 9.4 | |
| HF | Baker Bros Investments II LP | 2012-02-13 | 1.2 | |
| HF | Baker Bros Investments LP | 2012-02-13 | 9.8 | |
| HF | Baker Brothers Life Sciences LP | [2012-02-13] | 0.0 | 16,530.9 |
| HF | Baker/Tisch Investments LP | 2012-02-13 | 11.0 |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 18.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 18.0 |
| By Discretionary | ||
| Discretionary | 2 | 18.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 18.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 18.0 | |
| Total | 2 | 18.0 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 |
|---|---|---|---|
| General Partner Baker Brothers Life Sciences Capital LP | 14 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001263508] | |
| 3 | [0001263508] | |
| 4 | [0001263508] | |
| 5 | [0001263508] | |
| SC 13D | [0001263508] | |
| SC 13G | [0001263508] |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Pershing Square Capital Management LP
✚
|
NY | 18.3 |
|
Durable Capital Partners LP
✚
|
MD | 18.2 |
|
Blackstone Alternative Solutions LLC
✚
|
NY | 18.1 |
|
Allianz Investment Management LLC
✚
|
MN | 18.1 |
|
Alkeon Capital Management LLC
✚
|
NY | 18.1 |
|
Arga Investment Management LP
✚
|
CT | 18.0 |
|
Varde Management LP
✚
|
NY | 18.0 |
|
Appaloosa LP
✚
|
NJ | 17.7 |
|
Arini Capital Management Limited
✚
|
17.7 | |
|
Hildene Capital Management LLC
✚
|
CT | 17.3 |